This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since the first implementation in 2002 by Alain Cribier, transcatheter aorticvalve replacement (TAVR) has become a standard procedure for high-risk and elderly patients with severe aorticvalvestenosis. Recently, the use of TAVR has expanded to relatively younger patients with low to moderate surgical risk.
Bicuspid aorticvalve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aorticstenosis and regurgitation due to valve degeneration.
This Viewpoint advocates for prompt aorticvalve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aorticstenosis.
Transcatheter aorticvalve replacement (TAVR) has become a leading treatment for aorticstenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
Calcific aorticvalve disease (CAVD) is a common cardiovascular condition in the elderly population. Research has shown that lncRNAs participate in the pathological process underlying CAVD by regulating osteogenic differentiation and inflammatory response of valve interstitial cells.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aorticvalve system (Xcor system, Saint Medical Technology, Inc.,
Background Bicuspid aorticvalve (BAV) is the most common congenital heart defect in adults, often leading to complications such as thoracic aortic aneurysms and aorticstenosis. While BAV is frequently associated with 22q11.2
A significant proportion of patients with severe aorticstenosis (AS) undergoing transcatheter aorticvalve implantation (TAVI) have concomitant coronary artery disease (CAD). The best way to treat these patients is contentious.
IntroductionSince TAVR was approved for lower-risk aorticstenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aorticvalve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aorticstenosis who underwent successful TAVR.
AorticStenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
Valvular heart disease, including calcific or degenerative aorticstenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aorticvalve replacement (TAVR).
Background Cardiogenic shock (CS) induced by severe aorticstenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aorticvalve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aorticstenosis (narrowing of the aorticvalve).
The goal of the AVATAR trial was to evaluate aorticvalve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aorticstenosis.
(MedPage Today) -- Transcatheter aorticvalve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aorticvalve replacement, according to the EARLY TAVR.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aorticstenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Data shows, versus surgery, the Evolut transcatheter aorticvalve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Reardon, M.D.,
In the 22 years since Professor Alain Cribier performed the first transcatheter aorticvalve implantation (TAVI) in Rouen in France, treatment pathways for patients with aorticvalvestenosis have evolved rapidly.
Objectives The clinical outcomes of transcatheter aorticvalve replacement (TAVR) in patients with aorticstenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aorticvalve implantation (TAVI) compared with surgical aorticvalve replacement (SAVR) among patients with severe aorticstenosis and low to intermediate surgical risk.
Patients with severe aorticstenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aorticvalve replacement (AVR). The timing and magnit.
The goal of the NOTION trial was to compare outcomes after transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in unselected patients with severe degenerative aorticstenosis.
Objective Aorticstenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aorticvalve. HU, p=0.099).
The goal of the VIVA trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with surgical aorticvalve replacement (SAVR) among patients with severe aorticstenosis and a small aortic annulus.
Transcatheter aorticvalve replacement (TAVR) has increased in utilization since its approval for management of aorticstenosis patients across all risk strata. We report a rare case of aorticvalve leaflet av.
PurposeTo explore the expanding role of artificial intelligence (AI) in managing aorticvalvestenosis (AVS) by bibliometric analysis to identify research trends, key contributors, and the impact of AI on enhancing diagnostic and therapeutic strategies for AVS.MethodsA comprehensive literature review was conducted using the Web of Science database, (..)
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aorticstenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex. Specifically, 14.2%
Background Closure of paravalvular leak (PVL) regurgitation after self-expandable (SE) transcatheter aorticvalve implantation (TAVI) may be more challenging than after balloon-expandable (BE) valve implantation. MN, USA).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aorticvalve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aorticstenosis (AS).
Bicuspid aorticvalve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aorticstenosis and/or regurgitation, and is often associated with aortic root dilation.
Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aorticstenosis (AS) prior to transcatheter aorticvalve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. to 84.7%) and 74.6% (95% CI 65.9% to 93.5%) and 85.5% (95% CI 77.1%
Blaha, MD, MPH discuss Prevalence of AorticValve Calcium and the Long-Term Risk of Incident Severe AorticStenosis. In this interview, Richard A. Chazal MD, MACC and Michael J.
Rapid-deployment aorticvalve replacement (RDAVR) is an alternative to conventional AVR (cAVR) for aorticstenosis. Benefits include a reduction in operative times, facilitation of minimal access surgery and s.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content